
MediWound (MDWD) Stock Forecast & Price Target
MediWound (MDWD) Analyst Ratings
Bulls say
MediWound is supported by a differentiated wound-care portfolio that combines near-term commercial visibility from NexoBrid with a longer-duration growth option in EscharEx, while 2Q26 revenue of $3.1M beat expectations and full-year 2026 guidance of $24-26M was reaffirmed despite government contract timing uncertainty. The company’s outlook is strengthened by the 10-year BARDA contract valued at up to $197M, recovering NexoBrid shipments, and expected European regulatory clearance in 2H26 for the expanded manufacturing facility, which should support execution without altering the underlying guidance. Longer term, EscharEx remains the key value driver with VALUE Phase III topline data now expected in 2H27 and expansion into DFU and pressure ulcers under evaluation, giving the story meaningful upside beyond the current burn-care franchise.
Bears say
MediWound is facing a weak fundamental setup as NexoBrid’s capacity constraints persist, with EMA-requested modifications not expected to be completed until YE26 and facility approval slipping into 2H27, delaying commercial scale and forcing at-risk production to absorb demand. The reimbursement backdrop is also poor, since EU countries do not approve favorable reimbursement for NexoBrid in medium to severe burn wounds, contributing to weak revenue generation and continued unprofitability. On top of that, EscharEx’s initial revenues have been pushed further into 2028, and any disappointment in its P3 efficacy would further undermine the investment case.
This aggregate rating is based on analysts' research of MediWound and is not a guaranteed prediction by Public.com or investment advice.
MediWound (MDWD) Analyst Forecast & Price Prediction
Start investing in MediWound (MDWD)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About MediWound (MDWD) Forecast
MediWound (MDWD) Analyst Forecast & Price Prediction
Start investing in MediWound (MDWD)
Order type
Buy in
Order amount
Est. shares
0 shares